IMODIUM COMPLETE 125 MG — DIN 02245185
SIMETHICONE : 125 MG LOPERAMIDE HYDROCHLORIDE : 2 MG · MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is IMODIUM COMPLETE?
IMODIUM COMPLETE 125 MG contains SIMETHICONE : 125 MG LOPERAMIDE HYDROCHLORIDE : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02245185, held by MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 28-Nov-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is IMODIUM COMPLETE used for?
Adjunct to rehydration therapy for symptomatic control of acute, nonspecific diarrhea associated with gas-related abdominal discomfort (bloating, flatulence, cramping).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Loperamide, Combinations in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Loperamide, Combinations — 2 DINs, of which 1 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | 2 | 1 | IMODIUM COMPLETE, IMODIUM COMPLETE CHEWABLE TABLETS | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 125 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Blister packs of 20 and 40 caplets. |
| Storage | Not explicitly stated in provided text (standard template section 11 is listed in TOC but text ends at section 10.2). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Loperamide, Combinations |
|---|---|
| ATC code | A07DA53 |
| AHFS class | 56:08.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02245185 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2245185 |
| Brand name | IMODIUM COMPLETE |
| Generic / active ingredient | SIMETHICONE : 125 MG LOPERAMIDE HYDROCHLORIDE : 2 MG |
| Market authorization holder | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A07DA53 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A07DA |
| Current status | MARKETED |
| Status date | 28-Nov-2025 |
| Original market date | 2002-06-20 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults/Children 12+: 2 caplets initially, then 1 after each loose bowel movement. Max 4/day for 2 days. Take on empty stomach with 250mL water. Children 6-11: Only on medical advice.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; children <2 years; where constipation must be avoided; acute dysentery (blood in stools/fever); bacterial enterocolitis; acute ulcerative or pseudomembranous colitis.
Warnings and precautions
Discontinue if no improvement in 48h. Risk of serious cardiac events/death with high doses. Caution when driving (tiredness/dizziness). Potential for abuse/misuse as opioid substitute.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| IMODIUM COMPLETE CHEWABLE TABLETS | 2 MG | TABLET (CHEWABLE) | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | CANCELLED POST MARKET | 02237297 |
2 · Same class — other molecules in ATC A07DA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Loperamide | ALTI-LOPERAMIDE - 2MG CAPLET · ANTI-DIARRHEAL CAPLETS - 2MG · APO-LOPERAMIDE · DIAHALT CAPLETS - 2MG · +28 more | 39 | 14 | Yes |
| Loperamide, Combinations | IMODIUM COMPLETE · IMODIUM COMPLETE CHEWABLE TABLETS | 2 | 1 | Yes |
| Diphenoxylate | LOMOTIL | 1 | 1 | Yes |
| Opium | DIBAN CAP · DONNAGEL-PG CAP · DONNAGEL-PG LIQ · OPIUM CAMPHRE TANIN TAB | 5 | 0 | Not in Canada |
| Morphine, Combinations | CAMPHORATED OPIUM TINCTURE · PAREGORIQUE | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.